Categories
Markets

ACST Stock – (NASDAQ: ACST) is providing an update on the use

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the usage of its “at the market” equity offering program.

As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti may well issue as well as promote from time to time its everyday shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares were offered at prevailing market rates averaging US$1.0747 a share. No securities were marketed throughout the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will supply the Company with extra freedom in its continuous review process to explore as well as evaluate strategic options.

About Acasti – ACST Stock

Acasti is a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs using OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical evidence of efficacy and safety in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.

Forward Looking Statements – ACST Stock

Statements in that press release which aren’t statements of historical or current fact constitute “forward looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking claims include known and unknown risks, uncertainties, as well as other unknown factors that can cause the particular results of Acasti to be materially different from historical results and from any later outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this particular press release. Forward-looking assertions in that press release include, but aren’t confined to, statements or info about Acasti’s strategy, future operations as well as the review of its of strategic alternatives.

The forward-looking claims contained in this specific press release are expressly qualified in their entirety by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor area of Acasti’s site at www.acastipharma.com. All forward-looking assertions in this press release are produced as of the day of this particular press release.

ACST Stock – Acasti doesn’t undertake to update some such forward-looking statements whether as a consequence of info which is brand new, future events or perhaps otherwise, except as called for by law. The forward looking statements contained herein are also subject typically to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

Leave a Reply

Your email address will not be published. Required fields are marked *